Advanced targeted therapies have the potential to slow lung cancer growth and improve patient outcomes. according to a series of studies presented on Saturday at the 13th World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC) in San Fransisco.
Unlike traditional chemotherapy-based treatments that destroy cancerous and non-cancerous cells alike, targeted therapies are designed to inhibit only cancer cell replication and tumour growth and are generally well tolerated by patients.
"The studies presented at the WCLC confirm that targeted therapies are on the forefront of treatment innovation and show improved efficacy and prolonged progression-free survival time compared to chemotherapy and combination treatments," said Dr. David Gandara, WCLC program chair.
"Moreover, since the medicines are orally administered, patients can receive treatment in-home versus in a hospital setting, easing the burden on patients and caregivers," he added.